NCT06124404View on ClinicalTrials.gov

Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Mechanically Ventilated Patients
Interventions
DRUG

Remimazolam besylate

After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given

DRUG

Remimazolam besylate

After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given

DRUG

Remimazolam besylate

After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given

Trial Locations (1)

430022

Wuhan Union Hospital, Wuhan

All Listed Sponsors
collaborator

Yichang Humanwell Pharmaceutical Co., Ltd., China

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER